|
| Primary information |
|---|
| ID | 10855 |
| Therapeutic ID | Th1217 |
| Protein Name | Anti-inhibitor coagulant complex |
| Sequence | NA
|
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | 4-7 hours |
| Description | Anti-inhibitor coagulant complex is a freeze-dried sterile human plasma fraction with factor VIII inhibitor bypassing activity to be reconstituted for intravenous administration. Anti-inhibitor coagulant complex contains mainly non-activated factors II, IX, and X and mainly activated factor VII. It is manufactured from large pools of human plasma. |
| Indication/Disease | Controlling bleeding episodes or bleeding during surgery in patients who have hemophilia A or B with inhibitors. |
| Pharmacodynamics | Multiple interactions of the components in anti-inhibitor coagulant complex restore the impaired thrombin generation of hemophilia patients with inhibitors. In vitro, anti-inhibitor coagulant complex shortens the activated partial thromboplastin time of plasma containing factor VIII inhibitor. |
| Mechanism of Action | NA |
| Toxicity | FEIBA is associated with increased risk of thromboembolic events such as stroke, myocardial infarction, and deep vein thrombosis [FDA Label]. |
| Metabolism | NA |
| Absorption | NA |
| NA |
| Clearance | NA |
| Categories | Amino Acids, Peptides, and Proteins,Biological Factors,Blood and Blood Forming Organs,Blood Coagulation Factors,Blood Proteins,Coagulants,Hematologic Agents,Hemostatics,Proteins,Reversed Anticoagulation Activity |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Antifibrinolytic Agents: May enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human). Avoid combination |
| Target | Coagulation factor X,Prothrombin,Fibrinogen alpha chain,Fibrinogen beta chain,Coagulation factor XIII A chain,Coagulation factor V,Coagulation factor VIII,Coagulation factor VII |
| Brand Name | Feiba Nf |
| Company | NA |
| Brand Description | NA |
| Prescribed For | Controlling bleeding episodes or bleeding during surgery in patients who have hemophilia A or B with inhibitors. It should not be used to treat patients with other bleeding disorders. |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | Solid |
| Route of Administration | Intravenous |
| Recommended Dosage | 50-100 units/kg per dose (maximum: 100 units/kg [single dose], 200 units/kg/day [total daily dose]). Dosage and duration of treatment depend on the location and extent of bleeding and clinical condition of the patient. |
| Contraindication | Known anaphylactic or severe hypersensitivity to anti-inhibitor coagulant complex or any component of the formulation, including factors of the kinin generating system; disseminated intravascular coagulation (DIC); acute thrombosis or embolism (including myocardial infarction) |
| Side Effects | chest pain or discomfort |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |